Cargando…
Polycomb Target Genes Are Silenced in Multiple Myeloma
Multiple myeloma (MM) is a genetically heterogeneous disease, which to date remains fatal. Finding a common mechanism for initiation and progression of MM continues to be challenging. By means of integrative genomics, we identified an underexpressed gene signature in MM patient cells compared to nor...
Autores principales: | Kalushkova, Antonia, Fryknäs, Mårten, Lemaire, Miguel, Fristedt, Charlotte, Agarwal, Prasoon, Eriksson, Maria, Deleu, Sarah, Atadja, Peter, Österborg, Anders, Nilsson, Kenneth, Vanderkerken, Karin, Öberg, Fredrik, Jernberg-Wiklund, Helena |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901331/ https://www.ncbi.nlm.nih.gov/pubmed/20634887 http://dx.doi.org/10.1371/journal.pone.0011483 |
Ejemplares similares
-
Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target
por: Agarwal, Prasoon, et al.
Publicado: (2016) -
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions
por: Alzrigat, Mohammad, et al.
Publicado: (2016) -
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains
por: Alzrigat, Mohammad, et al.
Publicado: (2017) -
Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment
por: Duvefelt, Charlotte Fristedt, et al.
Publicado: (2015) -
A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
por: Nylund, Patrick, et al.
Publicado: (2021)